PHILADELPHIA – With a major gap remaining between the demographics of people enrolled in clinical trials and those most likely to use the drugs the FDA approves, the agency is pushing forward with new steps to tackle the complex problem, issuing a draft guidance on enhancing trial population diversity on Thursday. If successful, the move could complement the efforts of industry and its partners as they pursue everything from community outreach to simple logistical supports.